SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant momentum and volatility as investors react to positive FDA briefing documents regarding its mRNA flu vaccine candidate ahead of a key advisory committee vote. The community is actively debating the stock's long-term growth potential through its expanding oncology and rare disease pipeline, while also tracking high short interest that has fueled speculation of a potential short squeeze.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is currently a focal point for investors debating whether its aggressive acquisition strategy and high short interest signal an impending rebound or further downside following heavy share dilution. The community is sharply divided, with bulls pointing to the company's expanding backlog and defense partnerships, while vocal critics are focused on insider selling and the stock's poor recent performance.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Churchill Capital Corp XI is trending due to significant institutional accumulation and the building momentum surrounding the Agility Robotics commercialization narrative. Community sentiment remains focused on the potential for a major re-rating as investors compare the firm's strategic industrial partnerships to successful past robotics and infrastructure plays.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is seeing heightened community engagement driven by anticipation of a potential buyout, as investors weigh the impact of recent product approvals and the company's aggressive pipeline development in the GLP-1 adjunct space. While bullish participants point to valuable clinical assets as prime acquisition targets, others remain focused on navigating volatility and debating the impact of management's confrontational regulatory strategy on future valuation.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is seeing increased investor activity following a strong quarterly performance, where the company beat earnings expectations and raised full-year revenue guidance. The community is actively debating the durability of the DefenCath franchise post-reimbursement changes while highlighting the potential for long-term growth driven by pipeline expansion and recent executive leadership shifts.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is experiencing significant volatility and heavy volume as traders debate the company's pivot toward becoming an AI infrastructure backbone through its Private Connectivity Fabric and recent strategic acquisitions. While bulls point to massive hyperscaler deal potential and a critical fiber footprint as long-term catalysts, the stock faces intense selling pressure from institutional shorting and concerns regarding balance sheet constraints and legacy business decline.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as investors debate whether the recent double-digit share price slide represents a structural breakdown or a deep-value accumulation opportunity following an accelerated share buyback and cautious management guidance. Community sentiment is heavily polarized, with many retail investors expressing frustration over the persistent downtrend while active traders are aggressively positioning in LEAPs and accumulating common equity, betting on a technical bounce driven by the firm's core medical technology fundamentals.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is gaining positive momentum as investors rotate toward stable, high-margin payment leaders, bolstered by new partnerships with platforms like Bridge to expand stablecoin-linked cards globally. Market participants are actively tracking the stock's consolidation near key support levels, anticipating that continued growth in digital commerce and cross-border volume will drive a technical breakout.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Nuvation Bio is experiencing significant market volatility surrounding its earnings report as investors weigh the company's Ibtrozi commercial launch against concerns over patient retention in late-line treatments. Community sentiment remains split between long-term optimism regarding a potential buyout catalyst and frustration over recent downward price pressure and insider trading activity.

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics is trending as investors react to the company's shift from development to commercialization, with community discussion centered on the rollout of ZEVASKYN and anticipation for Q1 earnings. The conversation is heavily focused on potential short squeeze dynamics driven by high short interest, institutional accumulation, and the expectation of revenue acceleration through an expanding network of Qualified Treatment Centers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NVX Edmond is overqualified, which would normally be a good thing, but Natter is too old. They needed to resolve this matter before the ASX reporting deadline in July, as there are suspicions that these constant staff changes are linked to liquidity problems.

StockTwits Web

Novonix Limited - ADR

 Edmond is overqualified, which would normally be a good thing, but Natter is too old. They needed to resolve this matter before the ASX reporting deadline in July, as there are suspicions that these constant staff changes are linked to liquidity problems.

@slim_nesbit 

This company is a scam. Always was.